Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833268 · ClinicalTrials.gov registry record
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 228
- Enrollment target
NCT06833268 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 228 participants.
The verdict
NCT06833268 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 228 participants
- Enrollment target
Study Summary
This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic landscape.
Interventions
- OTHER No drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2025-01-20 |
| Est. Completion | 2025-06-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06833268
The ClinicalTrials.gov registry entry for NCT06833268 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No drug is the first listed.
NCT06833268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06833268 about?
NCT06833268 is a clinical study titled "Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan". This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic land...
What is the current status of trial NCT06833268?
This trial is currently completed. The enrollment target is 228 participants. The study started on 2025-01-20. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06833268?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06833268?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.